European Medicines Agency validates marketing authorisation application for sacituzumab govitecan-Hziy for the treatment of metastatic triple-negative breast cancer

Sacituzumab govitecan-hziy (SG) is a first-in-class therapy targeting Trop-2; high expression of this protein is associated with poor survival and relapse. Regulatory review of SG in metastatic triple-negative breast cancer is also underway in the UK.

Source:

European Medicines Agency